)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
NeuroSense Therapeutics
NeuroSense Therapeutics (NRSN) investor relations material
NeuroSense Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Advanced lead candidate PrimeC into late-stage clinical development with FDA-cleared Phase 3 program in ALS, following successful Phase 2b results and regulatory engagement.
Demonstrated statistically significant survival benefit in ALS, with a 65% reduction in risk of death and over 14-month median survival advantage, published in JAMA Neurology.
Expanded scientific visibility through conference presentations, new patents, and enhancement of the Scientific Advisory Board.
Financial highlights
Research and development expenses increased 8.8% year-over-year to $6.2 million, mainly due to higher share-based payments and salaries.
General and administrative expenses rose 16.6% year-over-year to $4.9 million, primarily from increased share-based compensation.
Net loss for 2025 was $11.1 million, compared to $10.2 million in 2024.
Cash position as of December 31, 2025 was approximately $0.2 million.
Outlook and guidance
Upcoming milestones include additional biomarker readouts from PARADIGM, Phase 2 Alzheimer's study results, and a pre-NDS meeting with Health Canada in May 2026.
Potential NDS submission in Canada and continued preparation for Phase 3 PARAGON trial in ALS.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NeuroSense Therapeutics
- PrimeC slowed ALS progression by 32.8% over 18 months and advances to Phase 3 in 2026.NRSN
Corporate presentation16 Mar 2026 - PrimeC slowed ALS progression by 32.8% and improved survival by 58% in Phase 2b trials.NRSNCorporate presentation30 Jan 2026
- Biotech seeks $150M to advance ALS drug PrimeC amid ongoing losses and regional risks.NRSNRegistration Filing29 Jan 2026
- Advancing ALS therapy to Phase III, with recent financings and ongoing Nasdaq compliance risks.NRSNRegistration Filing16 Dec 2025
- ALS drug developer registers shares for resale amid financial and geopolitical challenges.NRSNRegistration Filing16 Dec 2025
- Advancing ALS therapy to Phase 3 with new funding, but faces Nasdaq and geopolitical risks.NRSNRegistration Filing16 Dec 2025
- PrimeC slowed ALS progression by 32.8% over 18 months and advances to Phase 3 in 2026.NRSNCorporate Presentation12 Dec 2025
- PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope.NRSNStatus Update8 Dec 2025
- Up to 10 million shares offered via $30M equity line to fund neurodegenerative drug development.NRSNRegistration Filing29 Nov 2025
NeuroSense Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage